Assessment of two novel chemical entities in theamelioration of tau-related neuropathology andbehavioral impairment in the P301S mouse.

The onset of symptoms in Alzheimer’s Disease, Picks disease, progressive supranuclear palsy and
cortical basal degeneration are connected to the formation of insoluble deposits of the tau protein in
the brain, also known as neurofibrillary tangles (NFT). The Treventis Corporation has developed new
chemicals that are designed to prevent the formation of NFT, which may be useful for treating
Alzheimer’s disease. Genetically modified mice which develop NFTs in their brains have been
developed as animal models of Alzheimer’s disease, and are therefore useful to test the effects novel
treatments. This experiment will determine whether two novel chemicals can reduce the amount of
brain pathology and behavioural impairments in a mouse model of Alzheimer’s disease. This research
will benefit the Treventis Corporation, by determining whether these novel chemicals are effective and
thus potentially useful for humans with Alzheimer’s disease.

Faculty Supervisor:

Richard Brown

Student:

Partner:

Treventis Corporation

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Dalhousie University

Program: